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Summary. Activation of CD20, a cross-membrane ion
channel, induces cell cycle progression from G0 to G1 in B
lymphocytes. Subsequent activation of CD40, a membrane
receptor of the nerve growth factor receptor superfamily,
transits the B cells to the S phase. CD40 may also act
synergistically in combination with IL-4 (B lymphocytes) or
IL-3/IL-7 (B-cell precursors). We investigated the proliferative
responses of B-lineage acute lymphoblastic leukaemia (ALL)
cells to CD20/CD40 activation. In 18/56 ALL cases, CD20
activation resulted in significant increases in DNA synthesis.
Similar, although more moderate, effects were seen of
activation of CD40 in 10/44 cases. Responses to CD20 or
CD40 activation were independent of co-stimulation with
IL-3, IL-4 or IL-7, and various cocktails of the different
growth stimuli did not act synergistically.
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in vitro proliferation.
B-cell development is governed by an, as yet, incomplete
characterized series of haemopoietic growth factors and other
stimuli. Factors that exert growth stimulatory effects on
normal B-cell precursors include interleukin (IL)-3 and IL-7
(Lee et al, 1989; Namen et al, 1988; Saeland et al, 1991;
Skjonsberg et al, 1991).
CD20 is a 35/37 kD surface polypeptide expressed exclu-
sively on B cells. Onset of expression of CD20 takes place
before the appearance of cytoplasmic  chains and is
sustained during B-cell development until the plasma cell
stage (Rosenthal et al, 1983; Stashenko et al, 1981). In
normal B lymphocytes, activation of CD20 proteins with the
antibody 1F5 induces cell cycle transition from G0 to G1 but is
not sufficient to initiate DNA synthesis (Clark et al, 1985;
Clark & Ledbetter, 1986; Clark & Shu, 1987; Golay et al,
1985; Smeland et al, 1985). Activation of CD20 results in its
phosphorylation on serine and threonine residues (Oettgen
et al, 1983; Tedder & Schlossman, 1988) and increases the
influx of Ca2+ ions into the cells. The structural and
functional properties of CD20 indicate that the protein acts
as a cross-membrane ion channel (Bubien et al, 1993; Deans
et al, 1993).
CD40, a receptor of the nerve growth factor receptor
superfamily, is expressed on B cells, follicular dendritic cells,
normal basal and thymic epithelium, and several carcinoma
and melanoma cell lines (Clark et al, 1988; Paulie et al,
1989; Young et al, 1989). During B-cell development, the
appearance of CD40 on the cell membrane precedes the
expression of CD20 and immunoglobulin heavy chains
(Uckun et al, 1990). Activation of CD40 by either the
CD40 ligand or CD40 activating antibodies, in concert with
IL-4, induces proliferation and maturation of B lymphocytes
(Banchereau et al, 1991; Crawford & Catovsky, 1993;
Defrance et al, 1992; Maliszewski et al, 1993; Spriggs et al,
1992). Also, co-activation of CD20 and CD40 results in a full
mitogenic response of B lymphocytes (Gordon et al, 1987;
Ledbetter et al, 1987). B-cell precursors (BCP) proliferate in
response to CD40 activation only when co-stimulated with
IL-3, IL-7 or IL-10 (Larson & Le Bien, 1994; Saeland et al,
1993).
Here, we show the proliferation inducing effects of CD20
and CD40 activation on B-lineage acute lymphoblastic
leukaemia (ALL) cells, alone and in combination with
growth factors (IL-3, IL-4 and IL-7). Activation of CD20
resulted in a proliferative response of ALL cells in 18/58
(31%) cases; activation of CD40 induced DNA synthesis in
10/44 (23%) cases. With the exception of one case, no
synergistic effects of the various stimuli were seen. These data
show that responses of ALL cells to CD20/CD40 activation are
heterogenous and distinct from those of normal (pre-)B cells.
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MATERIALS AND METHODS
Isolation of cells. ALL cells were isolated from bone marrow
or peripheral blood by Ficoll-Hypaque (Nygaard, Oslo,
Norway), density gradient centrifugation as described pre-
viously (Touw et al, 1989). T cells were removed from the ALL
cell samples by E-rosette formation using 2-aminoethyliso-
thiouronium bromide (AET) treated sheep erythrocytes,
followed by sedimentation through Ficoll-Hypaque (Madsen
et al, 1980). Monocytes were removed by adherence to plastic
petri dishes at 378C for 1 h. In all cases informed consent was
obtained. The ALL cell samples were subjected to routine
diagnostic immunophenotyping with a panel of monoclonal
antibodies (MoAb). Six cases were classified as null-ALL
(patients 1–6), 36 as common-ALL (patients 7–41, 58), 11
as pre-B-ALL (patients 42–52) and five as B-ALL (patients
53–57) according to established criteria (van Dongen et al,
1988). Cells were used either fresh or after cryopreservation
using a controlled-freezing apparatus (Planer Biomed, Sun-
bury-on-Thames) (Touw et al, 1989).
Enriched fractions of normal peripheral blood B-lympho-
cytes were obtained using the same protocol.
DNA synthesis assay. DNA synthesis was assessed by uptake
of 3H-thymidine (3H-TdR, specific activity 2 Ci/mmol,
Amersham International, Amersham) as described (Delwel
et al, 1988). In brief, 0.2 105 cells were cultured in
triplicate in 96-well dishes (Greiner, Alphen a/d Rijn, The
Netherlands) for 3 and 7 d in 100l serum-free medium
(Touw et al, 1990). 18 h before harvesting on nitrocellulose
filters using a Titertek cell harvester (Flow Laboratories,
Irvine) 0.1Ci 3H-TdR was added to each well. 3H-TdR
incorporation was measured by liquid scintillation counting.
Growth factors and CD20 or CD40 activating antibodies.
Human IL-3 (Gist Brocades, Delft, The Netherlands) was used
at 100 U/ml; human IL-4 (Dr S. Clark, Genetics Institute
Cambridge, Mass.) was added to the cultures at a 1 : 5000
dilution of COS cell supernatant; human IL-7 (Dr L. Park,
Immunex Corp., Seattle, Wash.) was used at 100 U/ml. Anti-
CD40 monoclonal antibody (MoAb) 14G7, provided by Dr R.
A. W. van Lier (Central Laboratory of the Red Cross Blood
Transfusion Service, Amsterdam) was used at a 1 : 250
dilution of ascites. The CD20 activating MoAb 1F5 (Clark &
Ledbetter, 1986; Clark et al, 1985) (Dr E. A. Clark, University
of Washington, Seattle, Wash.) was used at a final con-
centration of 3g/ml.
Analysis of CD20 and CD40 expression. Expression of CD20
or CD40 was assessed by flow cytometry (FACScan) after
labelling of cells with either anti CD20 MoAb 1F5 (Clark et al,
1985) or the anti-CD40 MoAb 14G7 and goat anti-mouse
immunoglobulin coupled to fluorescein isothiocyanate
(GAM/FITC, Nordic Tilburg, The Netherlands).
RESULTS AND DISCUSSION
CD20 activation of ALL cells
Dose titration experiments performed with ALL cells from four
patients indicated that maximal stimulation of DNA synthesis
is seen at 1F5 concentrations of 1–10g/ml. A representa-
tive experiment is shown in Fig 1A. Parallel incubations with
control MoAb did not result in mitogenic responses (data
not shown). Proliferative responses to 1F5 (3g/ml) were
analysed in 58 cases of ALL. CD20 activation resulted in a
significant increase of DNA synthesis in 18 cases (Table I).
The (in)ability to induce DNA synthesis of 1F5 did not
correlate with the immunologic subtype of ALL. Therefore
differences of maturation phenotype of ALL did not explain
the heterogeneity in responses to CD20 activation. A
correlation was neither apparent between responses to
CD20 activation nor responses to IL-3 or IL-7 (Fig 2). In
fact, the random distributionof the plotted stimulation indices
indicates that each of the individual responses is independent
from any of the responses to the other growth stimuli. As
expected, flow cytrometric analysis with anti-CD20 showed
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Fig 1. (A) Response of human BCP-ALL cells to
titrated doses of the CD20 activating MoAb 1F5
in a 3H-TdR uptake assay. (B) Response
of peripheral B cells to serial dilutions of the
activating CD40 MoAb 14G7 in a 3H-TdR
uptake assay in the presence (squares) or
absence (triangles) of IL-4.
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that ALL cells of 1F5 responding cases expressed CD20. In
15/27 1F5 nonresponders analysed, the ALL cells expressed
CD20, indicating that in these cases the absence of response
to 1F5 was not caused by lack of CD20.
CD40 activation of ALL cells
In dose titration experiments, maximal stimulation of DNA
synthesis by CD40 activating antibody 14G7 was reached at
dilutions of 1 : 1000–1 : 250 (Fig 1B). In 10/44 ALL cases,
Table I. Proliferative responses of ALL cells to activation of CD20 in comparison to responses to IL-3 or IL-7.*
ALL No additive
Pt subtype to culture Anti-CD20 IL-3 IL-7 Irradiated cells‡
1 Null 1.30.6† 10.91.7 3.71.8 2.40.4 0.40.1
6 Null 10.70.2 25.26.5 50.87.6 18.01.2 0.70.1
10 Common 18.40.6 29.80.9 31.81.0 22.42.0 0.40.1
13 Common 8.80.2 59.11.6 18.41.3 17.11.7 0.60.1
15 Common 13.00.8 55.55.5 23.33.0 20.31.0 0.20.0
16 Common 13.40.9 20.63.1 n.d.§ 17.21.0 0.20.0
22 Common 3.80.1 9.32.1 18.44.2 6.30.5 0.40.2
30 Common 5.90.2 65.911 11.42.2 10.11.8 0.70.2
31 Common 5.90.5 78.27.2 20.02.1 27.33.5 0.50.2
32 Common 3.10.3 8.12.2 14.84.6 18.20.4 0.30.1
36 Common 2.60.4 13.12.3 6.62.0 2.30.6 0.70.1
58 Common 7.91.3 27.02.7 9.82.7 6.41.1 0.30.1
38 Common 7.12.2 14.73.3 21.06.9 10.31.9 1.40.2
43 Pre-B 10.51.8 23.36.0 18.95.1 19.11.4 1.00.0
44 Pre-B 29.61.9 87.39.7 58.110 69.33.0 0.30.2
45 Pre-B 19.31.0 39.08.0 27.51.4 31.03.4 0.30.2
50 Pre-B 2.20.6 24.91.0 6.61.4 2.20.4 0.40.1
57 B 19.41.8 32.01.0 27314.7 19.66.0 0.90.2
* Only cases responsive to CD20 activation have been included. In these cases, stimulationvalues (1F5 supplemented
versus non-supplemented controls) were >1.5.
† Data are from 3H-thymidine uptake assays and are expressed as mean counts per minute  100  standard
deviation of triplicate cultures.
‡ Cells were irradiated (25 Gy) before culture.
§ Not determined.
Table II. Proliferative response of ALL cells to activation of CD40 in comparison to responses to IL-3, IL-7 and CD20 activation.*
ALL No additive Irradiated
Pt subtype to culture Anti-CD40 IL-3 IL7 Anti-CD20 cells‡
1 Null 1.30.6† 9.62.4 3.71.8 2.40.5 10.91.7 0.40.1
11 Null 35.41.5 70.83.1 1214 33.50.2 35.81.4 0.40.1
8 Common 34922 56845 3418 33612 3898 0.60.1
14 Common 5.50.9 15.63.6 15.02.0 5.91.6 3.81.2 0.40.1
21 Common 5.60.6 32.31.3 16.81.9 12.21.5 8.91.2 0.20.1
26 Common 31.51.0 45.53.9 35.21.6 27.01.7 32.90.4 1.40.2
30 Common 5.90.2 12.41.9 11.42.1 10.11.8 65.911 0.70.2
48 Pre-B 17.63.9 28.90.8 25.71.1 10.74.0 19.81.2 0.40.1
50 Pre-B 2.20.6 5.50.2 6.51.4 2.20.4 24.91.0 0.30.1
52 Pre-B 3.20.0 8.00.6 16.22.3 2.00.4 3.61.3 0.60.1
55 B 1.80.0 5.00.3 1.80.5 2.00.2 1.90.3 0.40.1
* Only cases responsive to CD40 activation have been included. In these cases, stimulation values (14G7 supplemented versus non-
supplemented controls) were >1.5.
† Data are from 3H-thymidine uptake assays and are expressed as mean counts per minute 100  standard deviation of triplicate
cultures.
‡ Cells were irradiated (25 Gy) before culture.
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DNA synthesis was moderately enhanced by 14G7 (1 : 250
dilution, Table II).
Previously, Law et al (1990) could not demonstrate
mitogenic effects of CD40 activation in ALL cells. However,
the latter study was based on the analysis of eight cases of ALL
only (Law et al, 1990). The various immunological subtypes
of B-cell ALL were represented among the 10 14G7
responsive cases. No correlation was apparent between
responses to anti-CD40 and those to IL-3, IL-4, IL-7 or anti-
CD20 (Fig 2). All 14G7 responders expressed CD40 at levels
detectable by flow cytometry. In 6/8 14G7 nonresponders,
ALL cells expressed CD40, suggesting that in the majority of
cases non-responsiveness of ALL cells following CD40
stimulation is due to ineffective signalling.
Activation of CD20 and CD40 in combination with other stimuli
Certain stimuli act synergistically in inducing proliferative
responses in nonleukaemic (pre-)B cells. Particularly, this has
been demonstrated for the combined activation of CD20 and
CD40 (Gordon et al, 1987; Ledbetter et al, 1987), and for
activation of CD40 in combination with IL-4 (Banchereau
et al, 1991; Defrance et al, 1992; Maliszewski et al, 1993;
Spriggs et al, 1992), IL-3 or IL-7 (Saeland et al, 1993).
Proliferative responses of ALL cells to different combinations
of stimuli, in the context of activation of CD20 or CD40,
are summarized in Table III. Although additive effects
(1F5 IL-3; 1F5 IL-7; 1F514G7) were occasionally
seen, none of the combinations tested were synergistic,
except in a single case of ALL in which both the combinations
14G7 IL-3 and 14G7 IL-7 synergistically stimulated DNA
synthesis.
The response of ALL cells to activation of CD20 or CD40,
with or without the addition of cytokines, differ from those of
nonleukaemic (pre-)B cells. Whether this would indicate that
ALL cells generally display aberrant responses to CD20 and
CD40 activation is not clear. In normal B lymphocytes
activation of CD20 induces transition from G0 to G1 (Clark &
Ledbetter, 1986; Clark et al, 1985; Golay et al, 1985; Smeland
et al, 1985), whereas CD40 activation promotes the transition
from G1 to S phase of the cell cycle. Activation of both of these
molecules is required for transduction of a full mitogenic
signal (Golay et al, 1991; Gordon et al, 1987; Ledbetter et al,
1987). The observation that in certain cases ALL cells
proliferate in response to either CD20 or CD40 activation as a
single growth stimulus could be suggestive of a partial loss of
cell cycle control bypassing the necessity of cooperation of
signals for a mitogenic response. Further elucidation of
signalling properties of CD20 and CD40 in normal and
leukaemic (pre-)B cells is needed to clarify these issues.
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